Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Enhance Market Position

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize the company's market dynamics, enhance its appeal to investors, and align trading conditions with the interests of its shareholders. Following the split, shares will trade on the NYSE American under the current ticker 'CLDI' but with a new CUSIP number of 320703 408.

The reverse stock split will convert every 12 pre-split shares into one post-split share, with fractional shares being rounded up to the nearest whole share at the participant level. This adjustment will also proportionately affect outstanding options, warrants, and equity plan shares, though it will not alter the par value or the number of authorized shares. The initiative reflects Calidi Biotherapeutics' commitment to strengthening its market position and fostering long-term shareholder value as it continues to advance its proprietary technology in the fight against cancer.